STAT+: Pharmalittle: FDA increasingly pausing trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
The FDA is pressing pause on testing of experimental medicines more often, a side effect of the drug industry’s move into promising but less-proven technologies.
Rise and shine, another busy day is on the way. We can tell if only by the flurry of dispatches emanating
